Attached files

file filename
EX-32.1 - EX-32.1 - Inogen Incingn-ex321_201506307.htm
EX-32.2 - EX-32.2 - Inogen Incingn-ex322_201506308.htm
EX-31.2 - EX-31.2 - Inogen Incingn-ex312_201506306.htm
EX-31.1 - EX-31.1 - Inogen Incingn-ex311_2015063010.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

OR

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From              to             

Commission file number: 001-36309

 

INOGEN, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

33-0989359

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

 

326 Bollay Drive
Goleta, California

 

93117

(Address of principal executive offices)

 

(Zip Code)

(805) 562-0500

(Registrant’s telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x    No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨

  

Accelerated filer ¨

  

Non-accelerated filer x

  

Smaller reporting company ¨

 

  

 

  

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No x

As of July 31, 2015, the registrant had 19,347,033 shares of common stock, par value $0.001, outstanding.

 

 

 

 

 

 


 

TABLE OF CONTENTS

 

 

 

Part I – Financial Information

 

Page

Item 1.

 

Financial Statements (Unaudited)

 

3

 

 

Balance Sheets as of June 30, 2015 and December 31, 2014

 

3

 

 

Statements of Operations for the Three Months Ended June 30, 2015 and June 30, 2014 and Six Months Ended June 30, 2015 and June 30, 2014

 

5

 

 

Statement of Stockholders’ Equity for the Six Months Ended June 30, 2015

 

6

 

 

Statements of Cash Flows for the Six Months Ended June 30, 2015 and June 30, 2014

 

7

 

 

Condensed Notes to the Financial Statements

 

9

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

25

Item 3.

 

Quantitative and Qualitative Disclosures about Market Risk

 

43

Item 4.

 

Controls and Procedures

 

44

 

 

Part II – Other Information

 

 

Item 1.

 

Legal Proceedings

 

46

Item 1A.

 

Risk Factors

 

46

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

69

Item 6.

 

Exhibits

 

71

SIGNATURES

 

72

 

 

 

2


 

INOGEN, INC.

PART I – FINANCIAL INFORMATION

 

Item 1.  Financial Statements.

 

Inogen, Inc.

Balance Sheets

(unaudited)

(amounts in thousands)

 

 

June 30,

 

 

December 31,

 

 

2015

 

 

2014

 

Assets

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

$

51,822

 

 

$

56,836

 

Short-term investments

 

14,240

 

 

 

 

Accounts receivable, net of allowances of $6,299 and $3,745 as of June 30, 2015 and

 

 

 

 

 

 

 

December 31, 2014, respectively

 

24,765

 

 

 

19,349

 

Inventories, net of allowances of $168 and $141 as of June 30, 2015 and December 31, 2014,

 

 

 

 

 

 

 

respectively

 

9,308

 

 

 

7,616

 

Deferred cost of revenue

 

460

 

 

 

515

 

Income tax receivable

 

2,148

 

 

 

2,129

 

Deferred tax asset - current

 

4,976

 

 

 

4,976

 

Prepaid expenses and other current assets

 

1,723

 

 

 

1,122

 

Total current assets

 

109,442

 

 

 

92,543

 

Property and equipment

 

 

 

 

 

 

 

Rental equipment, net of allowances of $932 and $832 as of June 30, 2015 and December

 

 

 

 

 

 

 

31, 2014, respectively

 

52,597

 

 

 

48,359

 

Manufacturing equipment and tooling

 

4,271

 

 

 

3,985

 

Computer equipment and software

 

4,155

 

 

 

3,699

 

Furniture and equipment

 

778

 

 

 

649

 

Leasehold improvements

 

933

 

 

 

756

 

Land and building

 

126

 

 

 

126

 

Construction in process

 

400

 

 

 

193

 

Total property and equipment

 

63,260

 

 

 

57,767

 

Less accumulated depreciation

 

(31,086

)

 

 

(25,840

)

Property and equipment, net

 

32,174

 

 

 

31,927

 

Intangible assets, net

 

238

 

 

 

270

 

Deferred tax asset - noncurrent

 

15,248

 

 

 

15,248

 

Other assets

 

97

 

 

 

97

 

Total assets

$

157,199

 

 

$

140,085

 

 

 

See accompanying condensed notes to the financial statements.

 

 

 

3


 

Inogen, Inc.

Balance Sheets (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

 

June 30,

 

 

December 31,

 

 

2015

 

 

2014

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable and accrued expenses

$

17,181

 

 

$

11,273

 

Accrued payroll

 

4,257

 

 

 

4,066

 

Current portion of long-term debt

 

307

 

 

 

299

 

Warranty reserve - current

 

1,065

 

 

 

781

 

Deferred revenue - current

 

2,278

 

 

 

2,316

 

Total current liabilities

 

25,088

 

 

 

18,735

 

Long-term liabilities

 

 

 

 

 

 

 

Warranty reserve - noncurrent

 

541

 

 

 

334

 

Deferred revenue - noncurrent

 

3,155

 

 

 

2,176

 

Long-term debt, net of current portion

 

159

 

 

 

315

 

Other noncurrent liabilities

 

339

 

 

 

375

 

Total liabilities

 

29,282

 

 

 

21,935

 

Commitments and contingencies (Note 5)

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

Common stock, $0.001 par value per share; 200,000,000 authorized;

 

 

 

 

 

 

 

19,346,143 and 19,059,364 shares issued and outstanding as of June 30, 2015 and December

 

 

 

 

 

 

 

31, 2014, respectively

 

19

 

 

 

19

 

Additional paid-in capital

 

179,560

 

 

 

174,824

 

Accumulated deficit

 

(51,662

)

 

 

(56,693

)

Total stockholders' equity

 

127,917

 

 

 

118,150

 

Total liabilities and stockholders' equity

$

157,199

 

 

$

140,085

 

 

 

See accompanying condensed notes to the financial statements.

 

 

 

4


 

Inogen, Inc.

Statements of Operations

(unaudited)

(amounts in thousands, except share and per share amounts)

 

 

Three months ended

 

 

Six months ended

 

 

June 30,

 

 

June 30,

 

 

 

2015

 

 

 

2014

 

 

 

2015

 

 

 

2014

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales revenue

$

32,385

 

 

$

20,464

 

 

$

55,434

 

 

$

35,321

 

Rental revenue

 

11,644

 

 

 

9,929

 

 

 

22,347

 

 

 

18,705

 

Total revenue

 

44,029

 

 

 

30,393

 

 

 

77,781

 

 

 

54,026

 

Cost of revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales revenue

 

17,866

 

 

 

10,682

 

 

 

30,455

 

 

 

18,223

 

Cost of rental revenue, including depreciation of $2,944 and $2,503 for the three

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

months ended and $5,900 and $4,760 for the six months ended, respectively

 

5,341

 

 

 

4,597

 

 

 

10,481

 

 

 

8,751

 

Total cost of revenue

 

23,207

 

 

 

15,279

 

 

 

40,936

 

 

 

26,974

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit-sales revenue

 

14,519

 

 

 

9,782

 

 

 

24,979

 

 

 

17,098

 

Gross profit-rental revenue

 

6,303

 

 

 

5,332

 

 

 

11,866

 

 

 

9,954

 

Total gross profit

 

20,822

 

 

 

15,114

 

 

 

36,845

 

 

 

27,052

 

Operating expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

975

 

 

 

879

 

 

 

1,838

 

 

 

1,514

 

Sales and marketing

 

7,567

 

 

 

6,364

 

 

 

14,491

 

 

 

12,069

 

General and administrative

 

6,935

 

 

 

3,908

 

 

 

12,653

 

 

 

7,957

 

Total operating expense

 

15,477

 

 

 

11,151

 

 

 

28,982

 

 

 

21,540

 

Income from operations

 

5,345

 

 

 

3,963

 

 

 

7,863

 

 

 

5,512

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

(6

)

 

 

(203

)

 

 

(13

)

 

 

(336

)

Interest income

 

26

 

 

 

12

 

 

 

38

 

 

 

18

 

Change in fair value of preferred stock warrant liability

 

 

 

 

 

 

 

 

 

 

36

 

Other income (expense)

 

(51

)

 

 

4

 

 

 

(156

)

 

 

11

 

Total other expense, net

 

(31

)

 

 

(187

)

 

 

(131

)

 

 

(271

)

Income before provision for income taxes

 

5,314

 

 

 

3,776

 

 

 

7,732

 

 

 

5,241

 

Provision for income taxes

 

1,855

 

 

 

1,490

 

 

 

2,701

 

 

 

2,067

 

Net income

$

3,459

 

 

$

2,286

 

 

$

5,031

 

 

$

3,174

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share attributable to common stockholders (Note 2)

$

0.18

 

 

$

0.13

 

 

$

0.26

 

 

$

0.13

 

Diluted net income per share attributable to common stockholders (Note 2)

$

0.17

 

 

$

0.11

 

 

$

0.24

 

 

$

0.11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of shares used in calculating net income per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic common shares

 

19,310,064

 

 

 

18,201,661

 

 

 

19,239,218

 

 

 

13,843,803

 

Diluted common shares

 

20,672,414

 

 

 

20,146,915

 

 

 

20,617,342

 

 

 

15,826,754

 

 

 

See accompanying condensed notes to the financial statements.

 

 

 

5


 

Inogen, Inc.

Statement of Stockholders’ Equity

(unaudited)

(amounts in thousands, except share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

Total

 

 

Common stock

 

 

paid-in

 

 

Accumulated

 

 

stockholders'

 

 

Shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

equity

 

Balance, December 31, 2014

 

19,059,364

 

 

$

19

 

 

$

174,824

 

 

$

(56,693

)

 

$

118,150

 

Stock-based compensation

 

 

 

 

 

 

 

1,327

 

 

 

 

 

 

1,327

 

Employee stock purchase

 

18,551

 

 

 

 

 

 

342

 

 

 

 

 

 

342

 

Excess tax benefits from stock-based

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  compensation arrangements

 

 

 

 

 

 

 

2,688

 

 

 

 

 

 

2,688

 

Stock options exercised

 

268,228

 

 

 

 

 

 

379

 

 

 

 

 

 

379

 

Net income

 

 

 

 

 

 

 

 

 

 

5,031

 

 

 

5,031

 

Balance, June 30, 2015

 

19,346,143

 

 

$

19

 

 

$

179,560

 

 

$

(51,662

)

 

$

127,917

 

 

 

See accompanying condensed notes to the financial statements.

 

 

 

6


 

Inogen, Inc.

Statements of Cash Flows

(unaudited)

(amounts in thousands)

 

 

Six months ended June 30,

 

 

2015

 

 

2014

 

Cash flows from operating activities

 

 

 

 

 

 

 

Net income

$

5,031

 

 

$

3,174

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

6,908

 

 

 

5,586

 

Loss on rental units and other fixed assets

 

648

 

 

 

921

 

Provision for sales returns

 

1,291

 

 

 

1,178

 

Provision for doubtful accounts

 

1,118

 

 

 

571

 

Provision for rental revenue adjustments

 

4,286

 

 

 

3,411

 

Provision for inventory obsolescence

 

53

 

 

 

79

 

Provision for other inventory losses

 

60

 

 

 

 

Stock-based compensation expense

 

1,327

 

 

 

666

 

Decrease in fair value of preferred stock warrant liability

 

 

 

 

(36

)

Deferred tax assets

 

 

 

 

(284

)

Excess tax benefits from stock-based compensation arrangements

 

(2,688

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(12,111

)

 

 

(10,574

)

Inventories

 

(1,805

)

 

 

(1,932

)

Deferred costs of revenue

 

55

 

 

 

(142

)

Income tax receivable

 

2,669

 

 

 

87

 

Prepaid expenses and other current assets

 

(601

)

 

 

(595

)

Accounts payable and accrued expenses

 

5,923

 

 

 

3,190

 

Accrued payroll

 

191

 

 

 

(57

)

Warranty reserve

 

491

 

 

 

269

 

Deferred revenue

 

941

 

 

 

1,267

 

Income tax payable

 

 

 

 

1,435

 

Other noncurrent liabilities

 

(36

)

 

 

(54

)

Net cash provided by operating activities

$

13,751

 

 

$

8,160

 

Cash flows from investing activities

 

 

 

 

 

 

 

Purchases of available-for-sale investments

 

(20,557

)

 

 

 

Maturities of available-for-sale investments

 

6,317

 

 

 

 

Investment in intangible assets

 

(11

)

 

 

(180

)

Production and purchase of rental equipment

 

(6,485

)

 

 

(6,752

)

Purchases of property and equipment

 

(1,275

)

 

 

(603

)

Net cash used in investing activities

$

(22,011

)

 

$

(7,535

)

 

7


 

Inogen, Inc.

Statements of Cash Flows (continued)

(unaudited)

(amounts in thousands)

 

 

Six months ended June 30,

 

Cash flows from financing activities

2015

 

 

2014

 

Proceeds from borrowings

 

 

 

 

6,000

 

Proceeds from redeemable convertible preferred stock warrants and common stock

 

 

 

 

 

 

 

warrants exercised

 

 

 

 

467

 

Proceeds from stock options exercised

 

379

 

 

 

109

 

Proceeds from initial public offering

 

 

 

 

56,471

 

Costs associated with initial public offering

 

 

 

 

(4,911

)

Proceeds from employee stock purchase

 

342

 

 

 

 

Repayment of debt from investment in intangible assets

 

(163

)

 

 

(86

)

Repayment of borrowings

 

 

 

 

(3,150

)

Excess tax benefits from stock-based compensation arrangements

 

2,688

 

 

 

 

Net cash provided by financing activities

$

3,246

 

 

$

54,900

 

Net increase (decrease) in cash and cash equivalents

 

(5,014

)

 

 

55,525

 

Cash and cash equivalents, beginning of period

 

56,836

 

 

 

13,521

 

Cash and cash equivalents, end of period

$

51,822

 

 

$

69,046

 

Supplemental disclosures of cash flow information

 

 

 

 

 

 

 

Cash paid during the period for interest

 

15

 

 

 

317

 

Cash paid during the period for income taxes, net of refunds received

 

33

 

 

 

802

 

Non-cash transactions:

 

 

 

 

 

 

 

Deemed dividend on redeemable convertible preferred stock

 

 

 

 

987

 

 

 

See accompanying condensed notes to the financial statements.

 

 

8


 

Inogen, Inc.

Condensed Notes to the Financial Statements

(unaudited)

(amounts in thousands, except share and per share amounts)

 

1. General

a)

Basis of presentation

The unaudited financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair presentation for each of the periods presented. The results of operations for interim periods are not necessarily indicative of results to be achieved for full fiscal years or other interim periods.

Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One® systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or 7.0 pounds. The Company’s Inogen One G2® and Inogen One G3™ have up to 5 and 4.5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility.

Although portable oxygen concentrators represent the fastest-growing segment of the Medicare oxygen therapy market, the Company estimates based on 2013 Medicare data that patients using portable oxygen concentrators represent approximately 5% to 7% of the total addressable oxygen market in the United States. Based on 2013 industry data, the Company believes it was the leading worldwide manufacturer of portable oxygen concentrators, as well as the largest provider of portable oxygen concentrators to Medicare patients, as measured by dollar volume. The Company believes it is the only manufacturer of portable oxygen concentrators that employs a direct-to-consumer strategy in the United States, meaning the Company markets its products to patients, processes their physician paperwork, provides clinical support as needed and bills Medicare or insurance on their behalf. To pursue a direct-to-consumer strategy, the Company’s manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements and secure Medicare billing privileges, as well as compete with the home medical equipment providers that many rely on across their entire homecare business.

Since adopting the Company’s direct-to-consumer strategy in 2009 following its acquisition of Comfort Life Medical Supply, LLC, which had an active Medicare billing number but few other assets and limited business activities, the Company has directly sold or rented its Inogen One systems to more than 97,000 patients as of June 30, 2015.  Revenue has grown from $10,700 in 2009 to $112,500 in 2014.

As contemplated by the Securities and Exchange Commission (SEC) under Rule 10-01 of Regulation S-X, the accompanying financial statements and related footnotes have been condensed and do not contain certain information that will be included in the Company’s annual financial statements and footnotes thereto. For further information refer to the financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on April 27, 2015 (Annual Report).

b)

Use of estimates

The preparation of the Company’s financial statements in accordance with generally accepted accounting principles in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying condensed notes. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to inventory and rental asset valuations and write-downs, accounts receivable reserves and allowance for bad debts, returns and adjustments, stock compensation expense, impairment assessments, depreciation and amortization, income tax provision and uncertain tax positions, fair value of financial instruments, and fair values of acquired intangibles.  Actual results could differ materially from these estimates.

9


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

c)

Reclassifications

Certain reclassifications have been made to prior years’ financial statements to conform to current period financial statements’ presentation with no effect on previously reported financial position, results of operations or cash flows. These changes consisted of reclassifications to certain line items in the accompanying Statements of Operations and Statements of Cash Flows.

d)

Initial public offering (IPO)

The Company completed an initial public offering on February 20, 2014, and sold 3,529,411 shares to the public for $16.00 per share.  In addition, the selling stockholders sold 981,902 shares for a combined total of 4,511,313 shares sold in the offering.  The Company netted approximately $49,668 after the underwriters’ discount and other associated expenses. In connection with the completion of the Company’s IPO, the Company’s 9,546,140 shares of redeemable convertible preferred stock and 66,666 shares of convertible preferred stock were automatically converted into 14,259,647 shares of common stock.  Following the IPO, all warrants previously exercisable for preferred stock became exercisable for common stock.  The previously reported warrant liability associated with the convertible warrants was applied to additional paid-in capital.  During the six months ended June 30, 2014, the Company recognized a partial period deemed dividend of $987 for the time-frame the redeemable convertible preferred stock was outstanding during the period.  The Company had no redeemable convertible preferred stock or convertible preferred stock outstanding as of December 31, 2014 or June 30, 2015, respectively. As of June 30, 2015, the Company had 19,346,143 shares of common stock outstanding.

e)

Recent Accounting Pronouncements

Revenue Recognition:  In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers (Topic 606). The update supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled to those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.

Subsequent to June 30, 2015, the FASB decided to delay the effective date of ASU 2014-09 by one year.  The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date.  As such, the updated standard will be effective for us in the first quarter of 2018, with the option to adopt t in the first quarter of 2017.  The Company is currently evaluating the impact of the Company’s pending adoption of ASU 2014-09 on the Company’s financial statements and has not yet determined the method by which the Company will adopt the standard.

 

Interest: In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The update requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This update is effective for our fiscal year beginning January 1, 2016 with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial condition, results of operations or cash flows.

 

Intangibles - Goodwill and Other - Internal Use Software: In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other-Internal Use Software - Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. The update provides guidance on fees paid by an entity in a cloud computing arrangement and whether an arrangement includes a license to the underlying software. If a cloud computing arrangement includes a software license, then the entity should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the entity should account for the arrangement as a service contract. This update is effective for our fiscal year beginning January 1, 2016. The adoption of this standard is not expected to have a material effect on our financial condition, results of operations or cash flows.

 

 

10


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

2. Summary of significant accounting policies

Sales revenue

The Company generates revenue primarily from sales and rentals of its products. The Company’s products consist of its proprietary line of oxygen concentrators and related accessories. Other revenue, which is included in sales revenue on the Statements of Operations, comes from service contracts, extended warranty contracts and freight revenue for product shipments.

Revenue from product sales is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the customer is fixed or determinable; and (4) collectability is reasonably assured. Revenue from product sales is generally recognized upon shipment of the product. Provisions for estimated returns and discounts are made at the time revenue is recognized. Provisions for standard warranty obligations, which are included in cost of sales revenue on the Statements of Operations, are also provided for at the time revenue is recognized.

Revenue from the sale of the Company’s services is recognized when no significant obligations remain undelivered and collection of the receivables is reasonably assured. The Company offers extended service contracts on its Inogen One concentrator line for periods ranging from 12 to 24 months after the end of the standard warranty period. Revenue from these extended service contracts is recognized in income on a straight-line basis over the contract period.

Accruals for estimated standard warranty expenses are made at the time that the associated revenue is recognized. The provisions for estimated returns, discounts and warranty obligations are made based on known claims and discount commitments and estimates of additional returns and warranty obligations based on historical data and future expectations. The Company’s accrued warranty liability was $1,606 and $1,115 for future warranty costs as of June 30, 2015 and December 31, 2014, respectively.

 The Company also offers a lifetime warranty for direct-to-consumer sales. For a fixed price, the Company agrees to provide a fully functional oxygen concentrator for the remaining life of the patient. Lifetime warranties are only offered to patients upon the initial sale of oxygen equipment by the Company and are non-transferable. Product sales with lifetime warranties are considered to be multiple element arrangements within the scope of the Accounting Standards Codification (ASC) 605-25—Revenue Recognition-Multiple-Element Arrangements.

There are two deliverables when a product that includes a lifetime warranty is sold. The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years. The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient. These two deliverables qualify as separate units of accounting.

 

The revenue is allocated to the two deliverables on a relative selling price method. The Company has vendor-specific objective evidence of selling price for the equipment. To determine the selling price of the lifetime warranty, the Company uses its best estimate of the selling price for that deliverable as the lifetime warranty is neither separately priced nor is the selling price available through third-party evidence. To calculate the selling price associated with the lifetime warranties, management considered the profit margins of the overall business, the average estimated cost of lifetime warranties and the price of extended warranties. A significant estimate used to calculate the price and expense of lifetime warranties is the life expectancy of patients. Based on clinical studies, the Company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the Company estimates on average all patients will succumb to their disease within five years. The Company has taken into consideration that when patients decide to buy an Inogen portable oxygen concentrator with a lifetime warranty, they typically have already been on oxygen for a period of time, which can have a large impact on their life expectancy from the time the Company’s product is deployed.

After applying the relative selling price method, revenue from equipment sales is recognized when all other revenue recognition criteria for product sales are met. Lifetime warranty revenue is recognized using the straight-line method during the fourth and fifth year after the delivery of the equipment which is the estimated usage period of the contract based on the average patient life expectancy.

Shipping and handling costs for sold products and rental assets shipped to the Company’s customers are included on the Statements of Operations as part of cost of sales revenue and cost of rental revenue, respectively.

11


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

Revenue from the sales of used rental equipment is recognized upon shipment and when collectability is reasonably assured and other revenue recognition criteria are met. When a rental unit is sold, the related cost and accumulated depreciation are removed from their respective accounts, and any gains or losses are included in cost of sales revenue on the Statements of Operations.

 

Rental revenue

The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with ASC 840—Leases. The Company has separate contracts with each patient that are not subject to a master lease agreement with any payor. The Company evaluates the individual lease contracts at lease inception and the start of each monthly renewal period to determine if there is reasonable assurance that the bargain renewal option associated with the potential capped free rental period would be exercised. Historically, the exercise of such bargain renewal option is not reasonably assured at lease inception and most subsequent monthly lease renewal periods. If the Company determines that the reasonable assurance threshold for an individual patient is met at lease inception or at a monthly lease renewal period, such determination would impact the bargain renewal period for an individual lease. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term, which may include a portion of the capped rental period. To date, the Company has not deferred any amounts associated with the capped rental period. Amounts related to the capped rental period have not been material in the periods presented.

The lease term begins on the date products are shipped to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private payors, and Medicaid. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received although product was delivered and revenue was earned. Upon determination that an account is uncollectible, it is written-off and charged to the allowance. Amounts billed but not earned due to the timing of the billing cycle are deferred and recognized in income on a straight-line basis over the monthly billing period. For example, if the first day of the billing period does not fall on the first of the month, then a portion of the monthly billing period will fall in the subsequent month and the related revenue and cost would be deferred based on the service days in the following month.

Rental revenue is recognized as earned, less estimated adjustments. Revenue not billed at the end of the period is reviewed for the likelihood of collections and accrued. The rental revenue stream is not guaranteed and payment will cease if the patient no longer needs oxygen or returns the equipment. Revenue recognized is at full estimated allowable amounts; transfers to secondary insurances or patient responsibility have no net effect on revenue. Rental revenue is earned for that month if the patient is on service on the first day of the 30-day period commencing on the recurring date of service for a particular claim, regardless if there is a change in condition or death after that date.

Included in rental revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of unbilled rental revenue is based on historical trends and estimates of future collectability. In addition, the Company estimates potential future adjustments and write-offs of these unbilled amounts and includes these estimates in the allowance for adjustments and write-offs of rental revenue which is netted against gross receivables.

 

Fair value of financial instruments

The Company’s financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued expenses, debt and warrants. The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued expenses approximate fair values based on the short-term nature of these financial instruments.

The fair value of the Company’s debt approximates carrying value based on the Company’s current incremental borrowing rate for similar types of borrowing arrangements. Imputed interest associated with the Company’s non-interest bearing debt is insignificant and has been appropriately recognized in the respective periods.

12


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

Fair value accounting

ASC 820—Fair Value Measurements and Disclosures, creates a single definition of fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and states that a fair value measurement should be determined based on assumptions that market participants would use in pricing the asset or liability. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by ASC 820, are as follows:

 

Level input

  

Input definition

Level 1

  

Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

 

 

 

Level 2

  

Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

 

 

 

Level 3

  

Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

 

The Company obtained the fair value of its available-for-sale securities, which are not in active markets, from a third-party professional pricing service using quoted market prices for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The Company's professional pricing service gathers observable inputs for all of its fixed income securities from a variety of industry data providers (e.g., large custodial institutions) and other third-party sources. Once the observable inputs are gathered, all data points are considered and the fair value is determined. The Company validates the quoted market prices provided by its primary pricing service by comparing their assessment of the fair values against the fair values provided by its investment managers. The Company's investment managers use similar techniques to its professional pricing service to derive pricing as described above. As all significant inputs were observable, derived from observable information in the marketplace or supported by observable levels at which transactions are executed in the marketplace, the Company has classified its available-for-sale securities within Level 2 of the fair value hierarchy.

The following table summarizes fair value measurements by level for the assets measured at fair value on a recurring basis:

 

As of December 31, 2014

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Certificates of deposit

$

 

 

$

11,633

 

 

$

 

 

$

11,633

 

Total assets

$

 

 

$

11,633

 

 

$

 

 

$

11,633

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of June 30, 2015

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Certificates of deposit

$

 

 

$

23,587

 

 

$

 

 

$

23,587

 

Total assets

$

 

 

$

23,587

 

 

$

 

 

$

23,587

 

 

Cash Equivalents

The Company considers all short-term highly liquid investments with a maturity of three months or less to be cash equivalents. Cash equivalents primarily consist of funds held in money market accounts, which were $10,100 and $42,300 as of June 30, 2015 and December 31, 2014, respectively. Cash equivalents are recorded at cost plus accrued interest, which approximates fair value. Certificates of deposit are included in cash equivalents and short-term investments based on the maturity date of the security.

Investments

The Company considers investments with maturities greater than three months, but less than one year, to be short-term investments. Investments that have maturities of more than one year are classified as long-term investments. Investments are classified as available-for-sale and are reported at fair value with unrealized gains or losses, if any, reported, net of tax, in accumulated other comprehensive income. The fair value measurement of the investments had an immaterial impact on Other Comprehensive Income.  The Company does not have any other items which would be classified within Other Comprehensive Income.  Therefore, there would be no change between the reported Net Income and Other Comprehensive Income due to the immateriality of the unrealized gains or losses

13


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

associated with investments.  The cost of investments sold is based on the specific identification method, and all income generated and realized gains or losses from investments are recorded to interest and other income (expense), net.

The Company reviews its investments to identify and evaluate investments that have an indication of possible impairment. Factors considered in determining whether a loss is temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, and the Company's intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. Credit losses and other-than-temporary impairments are declines in fair value that are not expected to recover and are charged to interest and other income (expense), net.

 

Accounts receivable and allowance for bad debts, returns, and adjustments

Accounts receivable are customer obligations due under normal sales and rental terms. The Company performs credit evaluations of the customers’ financial condition and generally does not require collateral. The allowance for doubtful accounts is maintained at a level that, in management’s opinion, is adequate to absorb potential losses related to accounts receivable and is based upon the Company’s continuous evaluation of the collectability of outstanding balances. Management’s evaluation takes into consideration such factors as past bad debt experience, economic conditions and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their net realizable value.

The allowance is based on estimates, and ultimate losses may vary from current estimates. As adjustments to these estimates become necessary, they are reported in earnings in the periods that they become known. The allowance is increased by bad debt provisions charged to bad debt expense, net of recoveries, in operating expense and is reduced by direct write-offs, net of recoveries.

The Company generally does not allow returns from providers for reasons not covered under its standard warranty. Therefore, provision for sales returns applies to direct-to-consumer sales only. This reserve is calculated based on actual historical return rates under the Company’s 30-day return program and is applied to the sales revenue for direct-to-consumer sales for the last month of the quarter reported.

The Company also records an allowance for rental revenue adjustments and write-offs, which is recorded as a reduction of rental revenue and rental accounts receivable balances. These adjustments and write-offs result from contractual adjustments, audit adjustments, untimely claims filings or billings not paid due to another provider performing same or similar functions for the patient in the same period, all of which prevent billed revenue from becoming realizable. The reserve is based on historical revenue adjustments as a percentage of rental revenue billed and rental revenue unbilled during the related period.

When recording the allowance for doubtful accounts, the bad debt expense account (general and administrative expense account) is charged; when recording allowance for sales returns, the sales returns account (contra sales revenue account) is charged; and when recording the allowance for adjustments, the rental revenue adjustments account (contra rental revenue account) is charged.

As of June 30, 2015 and December 31, 2014, included in accounts receivable on the balance sheets were earned but unbilled receivables of $4,141 and $3,653, respectively. These balances reflect gross unbilled receivables prior to any allowances for adjustments and write-offs.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date.

Concentration of customers and vendors

The Company sells its products to home medical equipment providers, distributors, and resellers in the United States and in foreign countries on a credit basis. The Company sells its products to consumers on a prepayment basis. No single customer represented more

14


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

than 10% of the Company’s total revenue for the six months ended June 30, 2015 and June 30, 2014.  No single customer represented more than 10% of the Company’s total accounts receivable balance as of June 30, 2015, or as of December 31, 2014.

The Company also rents products directly to consumers for insurance reimbursement, which resulted in a customer concentration relating to Medicare’s service reimbursement programs. Medicare’s service reimbursement programs accounted for 73.1% and 71.7% of rental revenue for the three months ended June 30, 2015 and June 30, 2014, respectively, and based on total revenue were 19.3% and 23.4% for the three months ended June 30, 2015 and June 30, 2014, respectively. Medicare’s service reimbursement programs accounted for 72.9% and 72.1% of rental revenue for the six months ended June 30, 2015 and June 30, 2014, respectively, and based on total revenue were 21.0% and 25.0% for the six months ended June 30, 2015 and June 30, 2014, respectively. Accounts receivable balances relating to Medicare’s service reimbursement programs amounted to $7,488 or 30.2% of total accounts receivable as of June 30, 2015 as compared to $4,875, or 25.2% of total accounts receivable as of December 31, 2014.

The Company currently purchases raw materials from a limited number of vendors, which resulted in a concentration of three major vendors. The three major vendors supply the Company with raw materials used to manufacture the Company’s products. For the six months ended June 30, 2015, the Company’s three major vendors accounted for 21.6%, 17.7%, and 9.6%, respectively, of total raw material purchases.  For the six months ended June 30, 2014, the Company’s three major vendors accounted for 22.6%, 18.1% and 8.5%, respectively, of total raw material purchases.  

A portion of revenue is earned from sales outside the United States. Approximately 70% of the non-U.S. revenue for the three months and six months ended June 30, 2015 was invoiced in euros. We did not begin to invoice in euros until the fourth quarter of 2014. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the three months and six months ended June 30, 2015 and June 30, 2014 is as follows:

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

U.S. revenue

 

$

33,458

 

 

$

24,237

 

 

$

58,812

 

 

$

43,424

 

Non-U.S. revenue

 

 

10,571

 

 

 

6,156

 

 

 

18,969

 

 

 

10,602

 

Total revenue

 

$

44,029

 

 

$

30,393

 

 

$

77,781

 

 

$

54,026

 

 

 

 

Inventories

Inventories are stated at the lower of cost or market. Cost is determined using a standard cost method, including material, labor and manufacturing overhead, whereby the standard costs are updated at least quarterly to reflect approximate actual costs using the first-in, first out (FIFO) method and market represents the lower of replacement cost or estimated net realizable value. The Company records adjustments at least quarterly to inventory for potentially excess, obsolete, slow-moving or impaired items. Inventories consist of the following:

 

 

 

June 30,

 

 

December 31,

 

 

 

2015

 

 

2014

 

Raw materials and work-in-progress

 

$

8,118

 

 

$

6,774

 

Finished goods

 

 

1,358

 

 

 

983

 

Less: reserves

 

 

(168

)

 

 

(141

)

Inventories

 

$

9,308

 

 

$

7,616

 

 

 

Property and equipment

Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the assets’ estimated useful lives as follows:

 

Rental equipment

  

1.5-5 years

Manufacturing equipment and tooling

  

5 years

Computer equipment and software

  

3 years

Furniture and equipment

  

3-5 years

Leasehold improvements

  

Shorter of 3-10 years or life of underlying lease

15


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

 

Expenditures for additions, improvements and replacements are capitalized and depreciated to a salvage value of zero. Repair and maintenance costs are included in cost of revenue on the Statements of Operations. Repair and maintenance expense, which includes labor, parts and freight for rental equipment was $642 and $400 for the three months ended June 30, 2015 and June 30, 2014, respectively, and $1,212 and $790 for the six months ended June 30, 2015 and June 30, 2014, respectively.

Included within property and equipment is construction in process relating to the design and engineering of tooling, jigs and other machinery.  In addition, this item also includes computer software that has been purchased, but has not completed the final configuration process for implementation into the Company’s systems. These items have not been placed in service; therefore, no depreciation and amortization has been recognized in respective periods.

Depreciation and amortization expense related to property and equipment and rental equipment is summarized below for the three months ended June 30, 2015 and June 30, 2014, respectively, and for the six months ended June 30, 2015 and June 30, 2014, respectively.

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

Rental equipment

 

$

2,944

 

 

$

2,503

 

 

$

5,900

 

 

$

4,760

 

Other property and equipment

 

 

498

 

 

 

384

 

 

 

965

 

 

 

746

 

Total depreciation and amortization

 

$

3,442

 

 

$

2,887

 

 

$

6,865

 

 

$

5,506

 

 

 

Property and equipment and rental equipment with associated accumulated depreciation is summarized below for June 30, 2015 and December 31, 2014, respectively.

 

 

 

June 30,

 

 

December 31,

 

Property and equipment

 

2015

 

 

2014

 

Rental equipment, net of allowance

 

$

52,597

 

 

$

48,359

 

Other property and equipment

 

 

10,663

 

 

 

9,408

 

Property and equipment

 

 

63,260

 

 

 

57,767

 

 

 

 

 

 

 

 

 

 

Accumulated depreciation

 

 

 

 

 

 

 

 

Rental equipment

 

 

25,383

 

 

 

21,084

 

Other property and equipment

 

 

5,703

 

 

 

4,756

 

Accumulated depreciation

 

 

31,086

 

 

 

25,840

 

 

 

 

 

 

 

 

 

 

Net property and equipment

 

 

 

 

 

 

 

 

Rental equipment

 

 

27,214

 

 

 

27,275

 

Other property and equipment

 

 

4,960

 

 

 

4,652

 

Property and equipment, net

 

$

32,174

 

 

$

31,927

 

 

 

Income taxes

The Company accounts for income taxes in accordance with ASC 740—Income Taxes. Under ASC 740, income taxes are recognized for the amount of taxes payable or refundable for the current period and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax asset will not be realized.

The Company accounts for uncertainties in income tax in accordance with ASC 740-10—Accounting for Uncertainty in Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This accounting standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

The Company recognizes interest and penalties on taxes, if any, within operations as income tax expense. No significant interest or penalties were recognized during the periods presented.

16


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

The Company operates in multiple states. The statute of limitations has expired for all tax years prior to 2011 for federal and 2010 to 2011 for various state tax purposes. However, the net operating loss generated on the federal and state tax returns in prior years may be subject to adjustments by the federal and state tax authorities.

Income tax expense was $1,855 and $2,701, an effective tax rate of 34.9% and 34.9%, for the three and six months ended June 30, 2015, respectively, compared to $1,490 and $2,067, an effective tax rate of 39.5% and 39.4%, for the comparable periods ended June 30, 2014, respectively.  Variations in the tax rate year-over-year were primarily due to a decrease in permanent tax differences related to the domestic production activities deduction and the California research and development tax credit.

Accounting for stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which establishes accounting for share-based awards, exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation cost is determined at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee’s requisite service period.

As part of the provisions of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of stock compensation expense to be recognized in future periods.

Business segments

The Company operates in only one business segment – manufacturing, sales, rental and marketing of respiratory products.

 

 

Earnings per share

Earnings per share (EPS) is computed in accordance with ASC 260, Earnings per Share, and is calculated using the weighted-average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents (which can include dilution of outstanding stock options and common stock warrants) unless the effect is to reduce a loss or increase the income per share. For purposes of this calculation, common stock subject to repurchase by the Company, options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive.

The shares used to compute basic and diluted net income per share represent the weighted-average common shares outstanding, reduced by the weighted-average unvested common shares subject to repurchase.

 

17


Inogen, Inc.

Condensed Notes to the Financial Statements (continued)

(unaudited)

(amounts in thousands, except share and per share amounts)

 

The computation of EPS is as follows:

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

Numerator—basic:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

3,459

 

 

$

2,286

 

 

$

5,031

 

 

$

3,174

 

Less deemed dividend on redeemable convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

(987

)

Net income before preferred rights dividend

 

 

3,459

 

 

 

2,286

 

 

 

5,031